Doug Evans, PE, MBA, CEO, is a medical device executive with 25 years of industry and public company experience and an inventor/developer of dozens of medical products including the Angio-Seal Device. Mr. Evans was formerly COO and board member of Kensey Nash Corporation (acquired in 2012 by Royal DSM for $360M) and has authored over 175 patents.
John Nash, PE, Product Development Advisor, is a serial entrepreneur and inventor with over 250 patents, a product development expert and medical device executive. Mr. Nash was a co-founder of Kensey Nash Corporation where he developed and launched over 25 medical products in the cardiovascular, dental, orthopedic and regenerative medicine markets.
Linda Clark, RN, BSN, Global Director of Clinical Affairs, has more than 25 years of experience in critical care nursing and early stage start-up companies. She has managed and executed numerous clinical trials for novel devices from FIH to FDA completion and for CE mark approval. Her background includes trials in cardiology, cardiac surgery, neurosurgery and sleep apnea. She has held senior management positions for Abiomed Cardiovascular, Cardeon, Innercool, Paracor Medical, Respicardia and most recently LoneStar Heart.
Matt Gani, Director of Systems Engineering/R&D, has over 25 years of experience leading medical product development projects involving electrical stimulation, pacemaker, and defibrillator devices. Previously served as the VP of Product Development for Northstar Neuroscience, a developer of cortical stimulation therapies, as the Senior Director for Biotronik, and as PM for Telectronics Pacing Systems, acquired by St. Jude Medical.
Viral Thakkar, MSc, PEng, Director of Operations, holds a Masters degree in Mechanical Engineering from the University of Missouri-Rolla and 10 years of prior experience in managing and executing projects in R&D, product development, process improvements and cost reduction in medical device companies in the USA.
Shannon Kaustinen, CPA, CGA, Director of Finance and Administration, has 15 years of experience in financial accounting and controller roles with early stage private and publicly traded biotechnology firms including Zymeworks, iCo therapeutics, Protiva, Xenon Genetics and ID Biomedical, as well as broad experience as an independent financial consultant and public accountant.